You are using an outdated browser. Please upgrade your browser to improve your experience.

lutetium (177Lu) vipivotide tetraxetan

Ligand Summary
Ligand Structure
Rendered image for the query structure
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent. The active moiety of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177 which is linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer, including mCRPC. Upon binding of lutetium Lu 177 vipivotide tetraxetan to PSMA- expressing cells, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells, as well as to surrounding cells, and induces DNA damage which can lead to cell death.
Synonyms & Links
DrugCentral: 5509

Target Activities